

**Annual CAHH Meeting
October 8, 2018
Attendee Biographies**

Chair and Host of 2018 meeting:

Enrique Conterno, Senior Vice President and President, Lilly Diabetes and Lilly USA

Mr. Enrique Conterno is senior vice president of Lilly Diabetes and president of Lilly USA. Mr. Conterno joined Lilly in 1992 and has held a range of roles in sales, marketing, business development, and general management. Mr. Conterno earned a bachelor's degree in mechanical engineering from Case Western Reserve University and a master's degree in business administration from Duke University. He is a member of the Board of Governors at the American Red Cross, the Board of Visitors at Duke University's Fuqua School of Business and the board of directors at the Indiana Latino Institute. Mr. Conterno also is on the board of directors at the Indianapolis Chamber of Commerce, having served as board chair in 2016.



Co-Host of 2018 Meeting:

Mark Chance, Vice Dean for Research, CWRU School of Medicine

Dr. Mark Chance is an internationally recognized expert in proteomics and structural biology with over 250 publications who has built multiple internationally recognized science and training programs over a 25-year career in academia. As Vice Dean for Research at the School of Medicine, he has reshaped the strategic directions of the Academic Medical Center in research and graduate education to respond to current trends in biomedical research. He has led an innovation and commercialization program to develop therapeutics, the Council to Advance Human Health. He serves as the Director of the Center for Proteomics and Bioinformatics and as one of the leads for the Clinical and Translational Science Collaborative, is a member of numerous advisory boards and frequently invited lecturer at national and international meetings. He has multiple patents and patent filings and has launched a successful startup company in the field of precision medicine, NeoProteomics, Inc.



Discovery Experts

Michael Broder, President, Partnership for Health Analytic Research

Dr. Michael Broder has more than 20 years' experience in health economic and outcomes research. Dr. Broder received his research training in the Robert Wood Johnson Clinical Scholars Program at UCLA and RAND, attended medical school at Case Western Reserve University, and received his undergraduate degree from Harvard University. In addition to being an experienced health services researcher, he is a board-certified physician. Before starting PHAR, he served as Vice President of Zynx Life Sciences/Cerner Health Insights, a consulting and research firm in Beverly Hills, California. He is an Adjunct Professor at the Case Western Reserve School of Medicine and an Assistant Clinical Professor at the David Geffen School of Medicine at UCLA.



G. Alexander "Zan" Fleming, Executive Chairman and Founder, Kinexum

Dr. Zan Fleming has more than 25 years of industry and government experience in clinical research and medical and regulatory affairs, including extensive experience in diabetes, other metabolic and endocrine disorders, lipid-lowering compounds, and reproductive indications. He is the CEO and President of Kinexum LLC and previously served as Chief Scientific Officer and Senior Vice President of Global Regulatory Affairs of Ingenix Pharmaceutical Services, a division of UnitedHealth Group. Dr. Fleming received his medical training and laboratory research experience at Emory, Vanderbilt, and National Institutes of Health. Dr. Fleming completed fellowships in endocrinology at Vanderbilt and metabolism at NIH and holds an M.D. from Emory University School of Medicine.



David Geho, Head of Imaging, Vertex Pharmaceuticals, Inc.

Dr. David Geho recently became head of Imaging for Vertex Pharmaceuticals, Inc. in addition to his role as head of translational biology. Dr. Geho is a board certified physician who specializes in research and development, in particular imaging and translational medicine. Previously, Dr. Geho worked as the senior lead for translational medicine-oncology for Roche, clinical project leader for GE and the director of Imaging for Merck. Dr. Geho received his MD and PhD from Case Western Reserve University, and did a medical staff fellowship and residency at the National Cancer Institute.

Llew Keltner, Chief Executive Officer, EPISTAT

Llew Keltner, MD PhD, has a 40-year career in biopharma drug and business development. He is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management, and healthcare strategy company that he founded in 1972. Dr. Keltner is an Associate Professor at Case Western Reserve School of Medicine, and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine. He is currently a member of the American Society of Clinical Oncology, American Association of Cancer Research, American Medical Association, International Association of Tumor Marker Oncology, American Association of Clinical Chemistry, and Drug Information Association. Dr. Keltner received an MS in Epidemiology and Biostatistics, a PhD in Bioinformatics and an M.D. from Case Western Reserve University.



Yuling Luo, Founder, Chairman and CEO at Alamar Biosciences

Before starting Alamar Biosciences, Dr. Yuling Luo, Ph.D. co-founded Advanced Cell Diagnostics, Inc., in 2008 and served as the President and Chief Executive Officer. He co-founded Panomics (previously Genospectra, Inc.) in 2000 and served various roles including Group Leader of Gene Expression, Vice President of Functional Genomics and Chief Scientific Officer and he led the development and launch of all of its flagship product lines. Dr. Luo has over 14 years of experience in life science research. He serves as a Director of Advanced Cell Diagnostics, Inc. He holds a doctorate in biochemistry from Case Western Reserve University and conducted post-doctoral research at the University of Pennsylvania.

**Beno Michel, Clinical Consultant, Fluence Therapeutics; Scientific Advisor, BioMendics, Inc.**

Dr. Beno Michel, MD serves as clinical consultant of Fluence Therapeutics, Inc. and is a member of the scientific advisory board for BioMendics, Inc. In addition to a distinguished career as a dermatologist and a businessman, Dr. Michel founded several successful companies, served as Clinical Professor of Dermatology and Department Chair at Case Western Reserve University Medical School, served as President of the American Society of Dermatopathology, the Cleveland Dermatological Society and the Academy of Medicine of Cleveland and Northern Ohio. Dr. Michel graduated from the University Geneva and completed a fellowship in dermatology at the Mayo Clinic.

**Lawrence Posner, General Partner, Vendata Capital**

Dr. Lawrence Posner, MD retired from Bayer Pharmaceutical Corporation in 2003, where he served as senior vice president for research and development and worldwide head of regulatory affairs. After his retirement, Dr. Posner went back to school and earned his Master's in Economics at University of Connecticut. His focus is on health care policy and health care investments. Armed with his new degree, Dr. Posner now serves on corporate pharmaceutical boards – Labopharm, Inc, and Noxxon Pharma AG – and is a general partner at Vedanta Capital in New York City, where he specializes in health care investments. Dr. Posner earned his MD at Case Western Reserve University.

**David Scadden, Professor, Hematology/Oncology, Harvard University**

Dr. David Scadden is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He is a practicing hematologist/oncologist who focuses on bringing stem cell biology to patient care. He founded and directs the Center for Regenerative Medicine at the Massachusetts General Hospital and with Douglas Melton, co-founded and co-directs the Harvard Stem Cell Institute and the Harvard University Department of Stem Cell and Regenerative Biology. He is a member of the Institute of Medicine of the National Academies of Science, the Board of External Experts for the National Heart, Lung and Blood Institute and a former member of the National Cancer Institute's Board of Scientific Counselors.



William Slichenmyer, Partner, Alacrita

Prior to joining Alacrita, Mr. Slichenmyer had been part of executive management teams and led the development of innovative anticancer drugs while in the role of Chief Medical Officer at AVEO Oncology and Merrimack Pharmaceuticals. Earlier in his career, Mr. Slichenmyer held leadership and executive roles in large and small biopharma companies including Pfizer, Parke-Davis, Bristol-Myers Squibb, Hybridon and Burroughs-Wellcome. Mr. Slichenmyer has a BA (Chemistry) and MD degree from Case Western Reserve University, and a ScM degree in Clinical Investigation from Johns Hopkins University.

**Honored Guests****Bob Hurwitz, BioMendics, LLC, Co-Founder of OfficeMax, Founding Owner of the Coral Company**

In 1987, Mr. Hurwitz co-founded OfficeMax, Inc., where he was founding Chairman and CEO, building it into a national chain of office supply superstores. Mr. Hurwitz is also a founding owner of The Coral Company, a full service real estate development, construction and management firm. In 1996, Mr. Hurwitz founded Homeplace, Inc. which ultimately grew into a national chain of 100 home furnishings superstores before going into reorganization and eventually being sold. Since 2001 Mr. Hurwitz has engaged in assisting other entrepreneurs in developing their ideas and businesses. He is an active member on the Jumpstart Board and is involved on the organization's strategic planning, compensation, human resources and finance committees.

**Harvey Lodish, Founder and Scientific Board Member, Genzyme, Millennium Pharmaceuticals, Rubius Pharmaceuticals. Professor of Biological Engineering, MIT; Founding Member, the Whitehead Institute**

Dr. Harvey Lodish, PhD is a Professor at MIT and the Whitehead Institute for Biomedical Research and serves on the Board of Trustees of Boston Children's Hospital and Chair of the Board Research Committee. Dr. Lodish was a founder and Scientific Advisory Board Member of Genzyme, Inc and Millennium Pharmaceuticals, Inc. In 2014 he founded Rubius Pharmaceuticals, which had a successful IPO in July 2018. Dr. Lodish is a Member of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences, and has served on advisory panels for the Cleveland Clinic, NIH, NSF, and American Cancer Society, and on the advisory boards of several other institutions. Dr. Lodish received his A.B. degree Summa Cum Laude and with Highest Honors in Chemistry and Mathematics, from Kenyon College, and his Ph.D. degree in genetics from the Rockefeller University.

**Karen McGuire, CEO, Biomendics, LLC**

Dr. Karen McGuire is the CEO of BioMendics, LLC and works closely with the BioMendics team to ensure successful product development while providing substantial business opportunities to its investors. Dr. McGuire is a biomedical engineer with a doctorate in cellular & molecular biology and is focused on pharmacology and the development of natural products, proprietary molecules and liquid crystal biologics for cancer, orthopedics, wound care, metabolic and



inflammatory diseases. She has authored and co-authored several publications and patents with several patents currently pending.

Stephanie Oestreich, Executive Vice President, Head of BRIDGEs Partnerships North America, Evotec US Inc.

Dr. Stephanie Oestreich is the Executive Vice President, Head of BRIDGEs Partnerships North America for Evotec, building alliances with academics, biotechnology, pharma and financing partners. She received her PhD in biochemistry at Harvard Medical School and an MPA from the Harvard Kennedy School. Dr. Oestreich started in Strategic Alliances at Novartis in the US before moving to Switzerland to work for the CEO and taking on local, regional and global marketing roles in different geographies and therapeutic areas. From 2015 to 2017, Dr. Oestreich worked for F. Hoffmann La Roche as International Business Leader Avastin Breast, Cervical and Ovarian Cancer.



Iva Toudjarska, Senior Vice President, BRIDGEs Partnerships North America & NewCos, Evotec US, Inc.

Dr. Iva Toudjarska is part of the Evotec BRIDGEs North America team. Prior to joining Evotec, Dr. Toudjarska spent 6 years in Biopharma strategy consulting, and before that was a founding employee at Alnylam Pharmaceuticals. Dr. Toudjarska earned a Doctor of Philosophy from Bulgarian Academy of Sciences in Molecular Genetics and Masters of Business Administration from F.W. Olin Graduate School of Business at Babson College.



Investigators

Mitch Drumm, Professor, Pediatrics and Genetics and Genome Sciences


Dr. Mitchell Drumm received his BS in genetics from The Ohio State University in 1983 and his PhD in Human Genetics from the University of Michigan in 1990. His doctoral degree work was carried out in the laboratory of Francis Collins, MD, PhD, with whom he was a co-discoverer of the gene that causes cystic fibrosis (CF). Dr. Drumm continues to work on CF and joined the faculty at Case Western Reserve University in 1992 and is a Professor in the Departments of Pediatrics and Genetics and Genome Sciences. He has authored over 80 peer-reviewed manuscripts and several book chapters on cystic fibrosis and holds three patents relevant to the disease as well. In 2007, Dr. Drumm was appointed Director of Basic Research of the Willard A.

Bernbaum Cystic Fibrosis Research Center and in 2011 Vice Chair for Research in the Department of Pediatrics. Dr. Drumm also serves as an advisor to several cystic fibrosis research centers, reviews grants applications for the National Institutes of Health and co-chairs the Research and Research Training Committee of the Cystic Fibrosis Foundation.



John “Chip” Tilton, Associate Professor, Nutrition

Dr. John “Chip” Tilton, associate professor in the Department of Nutrition at Case Western Reserve University School of Medicine, maintains a research focus on understanding what makes cells susceptible to viral infection, but has more recently shifted to repurposing viruses for intracellular delivery of therapeutic proteins. Dr. Tilton was a clinical research fellow at the National Institutes of Health and a senior research investigator at the University of Pennsylvania before starting his lab at Case Western Reserve seven years ago. Dr. Tilton serves as Director of Immunobiology of the CWRU Center for Proteomics and Bioinformatics and holds a secondary appointment in the Department of Molecular Biology and Microbiology. Chip received his BA in Molecular Biology from Princeton University in 1995 and an MD from Yale University in 2001.



Anant Madabhushi, Professor, Biomedical Engineering

Dr. Anant Madabhushi is the F. Alex Nason Professor of biomedical engineering at Case Western Reserve University and director of the university’s Center for Computational Imaging and Personalized Diagnostics. Dr. Madabhushi has filed for patents for more than four dozen inventions and currently holds 24 patents in medical imaging analysis, computer vision and computer-aided diagnosis. Dr. Madabhushi is a Wallace H. Coulter Fellow and a fellow of the American Institute of Medical and Biological Engineering. In 2015, he made Crain’s Business Cleveland magazine’s “Forty under 40” list. He also was the recipient of an Early Career Lung Cancer Grant from the Department of Defense in 2014 and an Early Career Award from the Society of Imaging Informatics in Medicine (SIIM) in 2009.



CWRU Staff

Anne DeChant, Assistant Director, Translation and Innovation

Ms. Anne DeChant, MS, MBA, is Assistant Director, Office of Translation and Innovation, School of Medicine, Case Western Reserve University. She has worked at the university for over 16 years and currently serves as a member of the Office of the Vice-Dean for Research and the Clinical and Translational Science Collaborative. Ms. DeChant received a BS in Biology from The Ohio State University, a MS in Cell and Molecular Biology from Cleveland State University and an MBA from Case Western Reserve University Weatherhead School of Management.



Daria Fedyukina, Translational Officer

Dr. Daria Fedyukina works as a business analyst and translational officer at the CWRU School of medicine. Previously, Dr. Fedyukina spent many years in management and consulting with RegenxBio, L.E.K. Consulting, and LG Chem, in areas of commercialization, portfolio planning, business development, and life sciences strategy consulting. Dr. Fedyukina received her PhD from the University of Wisconsin.



Bill Harte, Chief Translational Officer

Dr. Bill Harte is a pharmaceutical executive with more than 25 years of experience in pharmaceutical/biotech research. Dr. Harte currently serves as the Chief Translational Officer at Case Western Reserve University, managing more than 20 translational research programs and supporting the School of Medicine's innovation pipeline. Dr. Harte previously co-founded E3x Bio, served as CEO of Visum Therapeutics, and spent years in pharma at Amgen and Bristol-Myers Squibb. Dr. Harte received a BS in Chemistry from Carnegie Mellon University and his PhD in Chemistry from Wesleyan University.



Steve Fening, Director, Case-Coulter Translational Research Partnership

Dr. Stephen Fening is the Director of the Case-Coulter Translational Research Partnership (CCTRP) in the Department of Biomedical Engineering at Case Western Reserve University. He received undergraduate and master's degrees in mechanical engineering, and a PhD in biomedical engineering. Dr. Fening is a co-founder and Chief Technology Officer of Apto Orthopaedics Corporation. He also has served on the board of directors for several for- and not-for-profits. Dr. Fening previously served as Director of Orthopaedic Devices at the Austen BioInnovation Institute in Akron and the Director of Orthopaedic Research for Summa Health Systems.



Michael Haag, Executive Director, Technology Management

Mr. Michael Haag, MS, MBA is the Executive Director of Technology Management at Case Western Reserve University. Mr. Haag is responsible for all intellectual property services at the university. Mr. Haag also serves as the managing director of CWRU Technology Ventures, and as president and CEO of ReXceptor, Inc. Mr. Haag received his BS in biology and chemistry from John Carroll University, his MS in biology from Case Western Reserve University, and his MBA from University of Phoenix.

**Carol Moss, Vice President for Health Sciences Development, Vice President for Medical External Affairs**

Ms. Carol Moss, MBA leads development efforts at the CWRU School of Medicine in her dual role as vice president for health sciences development, and vice president for medical external affairs. Ms. Moss previously served as vice chancellor for development and alumni relations at UCSF and chair of the division of institutional relations and development at Cleveland Clinic. Ms. Moss also serves on the board of directors of The First Tee Cleveland.

**Stacy Langenderfer, Senior Director of Development, Basic and Translational Sciences**

Ms. Stacy Langenderfer serves as the basic and translational sciences senior director of development for the CWRU School of Medicine. Ms. Langenderfer has over 10 years of experience in the health care industry, including previous work at University Hospitals of Cleveland and Pfizer.

**Rebecca Mason, Executive Director for Development Programs**

Ms. Rebecca Mason works in the Office of Development, currently serving as the Executive Director for Development Programs. Ms. Mason brings over 20 years of experience in communications and development from around the globe.

